{"nctId":"NCT00366899","briefTitle":"Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants","startDateStruct":{"date":"2006-10"},"conditions":["Vaccines, Pneumococcal"],"count":605,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent pneumococcal conjugate vaccine"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 7 valent pneumococcal conjugate vaccine"]}],"interventions":[{"name":"13-valent pneumococcal conjugate vaccine","otherNames":[]},{"name":"7 valent pneumococcal conjugate vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Aged 3 months (75 to 105 days) at time of enrollment.\n2. Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.\n3. Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.\n4. Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.\n5. Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.\n\nExclusion criteria:\n\n1. Previous vaccination with licensed or investigational pneumococcal vaccine.\n2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.\n3. A previous anaphylactic reaction to any vaccine or vaccine-related component.\n4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.\n5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.\n6. Known or suspected immune deficiency or suppression.\n7. History of culture-proven invasive disease caused by S pneumoniae or Hib.\n8. Major known congenital malformation or serious chronic disorder.\n9. Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.\n10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® \\[MedImmune\\]).\n11. Participation in another investigational trial. Participation in purely observational studies was acceptable.\n12. Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.","healthyVolunteers":true,"sex":"ALL","minimumAge":"75 Days","maximumAge":"105 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Reporting Pre-Specified Local Reactions","description":"Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\>7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null},{"groupId":"OG001","value":"30.0","spread":null},{"groupId":"OG002","value":"30.4","spread":null},{"groupId":"OG003","value":"36.7","spread":null},{"groupId":"OG004","value":"47.2","spread":null},{"groupId":"OG005","value":"44.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"3.5","spread":null},{"groupId":"OG002","value":"4.5","spread":null},{"groupId":"OG003","value":"5.0","spread":null},{"groupId":"OG004","value":"8.5","spread":null},{"groupId":"OG005","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"19.6","spread":null},{"groupId":"OG002","value":"24.6","spread":null},{"groupId":"OG003","value":"28.7","spread":null},{"groupId":"OG004","value":"28.6","spread":null},{"groupId":"OG005","value":"27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":null},{"groupId":"OG001","value":"18.3","spread":null},{"groupId":"OG002","value":"21.7","spread":null},{"groupId":"OG003","value":"26.4","spread":null},{"groupId":"OG004","value":"26.4","spread":null},{"groupId":"OG005","value":"21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"3.1","spread":null},{"groupId":"OG002","value":"5.6","spread":null},{"groupId":"OG003","value":"5.1","spread":null},{"groupId":"OG004","value":"7.5","spread":null},{"groupId":"OG005","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null},{"groupId":"OG001","value":"26.5","spread":null},{"groupId":"OG002","value":"31.5","spread":null},{"groupId":"OG003","value":"34.4","spread":null},{"groupId":"OG004","value":"36.5","spread":null},{"groupId":"OG005","value":"36.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"24.6","spread":null},{"groupId":"OG002","value":"28.4","spread":null},{"groupId":"OG003","value":"32.2","spread":null},{"groupId":"OG004","value":"32.6","spread":null},{"groupId":"OG005","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"5.5","spread":null},{"groupId":"OG003","value":"3.6","spread":null},{"groupId":"OG004","value":"7.5","spread":null},{"groupId":"OG005","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Pre-Specified Systemic Events","description":"Systemic events (fever ≥ 37.5 degrees Celsius \\[C\\], fever ≥ 38 C but ≤ 39 C, fever \\>39 C but ≤ 40 C, fever \\> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"38.6","spread":null},{"groupId":"OG002","value":"55.5","spread":null},{"groupId":"OG003","value":"60.6","spread":null},{"groupId":"OG004","value":"63.7","spread":null},{"groupId":"OG005","value":"52.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"4.7","spread":null},{"groupId":"OG002","value":"6.9","spread":null},{"groupId":"OG003","value":"7.0","spread":null},{"groupId":"OG004","value":"9.6","spread":null},{"groupId":"OG005","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"34.3","spread":null},{"groupId":"OG002","value":"47.3","spread":null},{"groupId":"OG003","value":"45.4","spread":null},{"groupId":"OG004","value":"52.0","spread":null},{"groupId":"OG005","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"63.7","spread":null},{"groupId":"OG002","value":"75.5","spread":null},{"groupId":"OG003","value":"75.3","spread":null},{"groupId":"OG004","value":"74.7","spread":null},{"groupId":"OG005","value":"74.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8","spread":null},{"groupId":"OG001","value":"64.5","spread":null},{"groupId":"OG002","value":"57.1","spread":null},{"groupId":"OG003","value":"56.5","spread":null},{"groupId":"OG004","value":"53.8","spread":null},{"groupId":"OG005","value":"54.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"36.4","spread":null},{"groupId":"OG002","value":"40.1","spread":null},{"groupId":"OG003","value":"41.8","spread":null},{"groupId":"OG004","value":"35.6","spread":null},{"groupId":"OG005","value":"35.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null},{"groupId":"OG001","value":"30.6","spread":null},{"groupId":"OG002","value":"43.4","spread":null},{"groupId":"OG003","value":"47.8","spread":null},{"groupId":"OG004","value":"53.1","spread":null},{"groupId":"OG005","value":"43.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"18.1","spread":null},{"groupId":"OG002","value":"20.2","spread":null},{"groupId":"OG003","value":"24.5","spread":null},{"groupId":"OG004","value":"27.9","spread":null},{"groupId":"OG005","value":"24.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose","description":"Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"93.1","spread":null},{"groupId":"OG002","value":"98.40","spread":null},{"groupId":"OG003","value":"98.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null},{"groupId":"OG001","value":"90.3","spread":null},{"groupId":"OG002","value":"99.6","spread":null},{"groupId":"OG003","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.9","spread":null},{"groupId":"OG001","value":"48.7","spread":null},{"groupId":"OG002","value":"96.2","spread":null},{"groupId":"OG003","value":"92.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"96.3","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"92.5","spread":null},{"groupId":"OG002","value":"97.6","spread":null},{"groupId":"OG003","value":"93.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"99.6","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"98.9","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null},{"groupId":"OG001","value":"95.2","spread":null},{"groupId":"OG002","value":"92.8","spread":null},{"groupId":"OG003","value":"95.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null},{"groupId":"OG001","value":"95.6","spread":null},{"groupId":"OG002","value":"95.2","spread":null},{"groupId":"OG003","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":null},{"groupId":"OG001","value":"95.2","spread":null},{"groupId":"OG002","value":"94.9","spread":null},{"groupId":"OG003","value":"95.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose","description":"GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.87","spread":null},{"groupId":"OG001","value":"105.17","spread":null},{"groupId":"OG002","value":"463.23","spread":null},{"groupId":"OG003","value":"456.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.01","spread":null},{"groupId":"OG001","value":"48.44","spread":null},{"groupId":"OG002","value":"60.89","spread":null},{"groupId":"OG003","value":"64.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167.76","spread":null},{"groupId":"OG001","value":"166.19","spread":null},{"groupId":"OG002","value":"339.30","spread":null},{"groupId":"OG003","value":"361.70","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose","description":"Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose","description":"Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"526.69","spread":null},{"groupId":"OG001","value":"1276.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191.34","spread":null},{"groupId":"OG001","value":"2383.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3585.80","spread":null},{"groupId":"OG001","value":"16384.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1882.96","spread":null},{"groupId":"OG001","value":"1903.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"294.48","spread":null},{"groupId":"OG001","value":"1324.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222.86","spread":null},{"groupId":"OG001","value":"391.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"487.51","spread":null},{"groupId":"OG001","value":"3679.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.63","spread":null},{"groupId":"OG001","value":"294.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176.07","spread":null},{"groupId":"OG001","value":"504.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.11","spread":null},{"groupId":"OG001","value":"333.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"541.81","spread":null},{"groupId":"OG001","value":"2217.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5914.33","spread":null},{"groupId":"OG001","value":"14886.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157.59","spread":null},{"groupId":"OG001","value":"1415.08","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose","description":"GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"260.46","spread":null},{"groupId":"OG001","value":"272.67","spread":null},{"groupId":"OG002","value":"1655.30","spread":null},{"groupId":"OG003","value":"2284.95","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose","description":"GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":null},{"groupId":"OG001","value":"1.00","spread":null},{"groupId":"OG002","value":"9.09","spread":null},{"groupId":"OG003","value":"8.85","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose","description":"GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.67","spread":null},{"groupId":"OG002","value":"2.77","spread":null},{"groupId":"OG003","value":"3.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":null},{"groupId":"OG001","value":"0.63","spread":null},{"groupId":"OG002","value":"2.62","spread":null},{"groupId":"OG003","value":"2.09","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose","description":"GMC of Polio as measured using a polio in vitro plaque neutralization.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180.72","spread":null},{"groupId":"OG001","value":"207.17","spread":null},{"groupId":"OG002","value":"924.52","spread":null},{"groupId":"OG003","value":"1348.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.74","spread":null},{"groupId":"OG001","value":"130.39","spread":null},{"groupId":"OG002","value":"1141.62","spread":null},{"groupId":"OG003","value":"1340.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"397.32","spread":null},{"groupId":"OG001","value":"452.14","spread":null},{"groupId":"OG002","value":"1567.64","spread":null},{"groupId":"OG003","value":"2421.31","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose","description":"Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"66.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":null},{"groupId":"OG001","value":"76.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null},{"groupId":"OG001","value":"70.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"53.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"32.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"83.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null},{"groupId":"OG001","value":"87.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"86.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"90.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"96.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose","description":"Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":null},{"groupId":"OG001","value":"0.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":null},{"groupId":"OG001","value":"0.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":null},{"groupId":"OG001","value":"0.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":null},{"groupId":"OG001","value":"2.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":null},{"groupId":"OG001","value":"0.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":null},{"groupId":"OG001","value":"0.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":null},{"groupId":"OG001","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":null},{"groupId":"OG001","value":"0.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":null},{"groupId":"OG001","value":"0.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":null},{"groupId":"OG001","value":"0.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":null},{"groupId":"OG001","value":"0.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.87","spread":null},{"groupId":"OG001","value":"1.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose","description":"Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"98.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"70.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"86.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose","description":"Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","spread":null},{"groupId":"OG001","value":"7.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":null},{"groupId":"OG001","value":"10.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"4.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.30","spread":null},{"groupId":"OG001","value":"11.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.83","spread":null},{"groupId":"OG001","value":"4.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.01","spread":null},{"groupId":"OG001","value":"8.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.43","spread":null},{"groupId":"OG001","value":"4.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.76","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":null},{"groupId":"OG001","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.59","spread":null},{"groupId":"OG001","value":"0.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.78","spread":null},{"groupId":"OG001","value":"1.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.31","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.81","spread":null},{"groupId":"OG001","value":"4.24","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":303},"commonTop":["Irritability","Increased sleep","Fever ≥38°C but ≤39°C","Decreased appetite","Irritability"]}}}